Meeting
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
Authors
Gilles A. Salles
Lyon Sud University Hospital, Pierre-Bénite, France
Gilles A. Salles , Nicole Lamanna , Bipinkumar R. Amin , Ralph V. Boccia , Nashat Y. Gabrail , Muhammad-Ali A. Zaydan , Michelle Wong , Adeboye H. Adewoye , Paolo Ghia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01980888
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7123)
DOI
10.1200/jco.2014.32.15_suppl.tps7123
Abstract #
TPS7123
Poster Bd #
406A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Herbert Aaron Eradat
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
First Author: Sven De Vos
Poster
2013 ASCO Annual Meeting
A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
First Author: Ian Flinn